Exercise-mimetic peptides: MOTS-c, SS-31 and the irisin question

Exercise is, by a wide margin, the most robustly evidenced intervention in ageing biology, with effects spanning cardiovascular function, muscle mass preservation, cognitive performance and all-cause mortality risk across dozens of large cohort studies. This is worth stating first because it frames what 'exercise-mimetic' peptide research is actually claiming: partial reproduction of specific downstream pathways, not a replacement for exercise itself.

MOTS-c is the clearest example of this framing in the current peptide literature. Reynolds et al. (2021, Nature Communications) demonstrated that MOTS-c administration in aged mice reproduced a substantial portion of the transcriptional and metabolic adaptations normally induced by exercise training, including improvements in exercise capacity and skeletal-muscle metabolic gene expression, without the animals undergoing an exercise protocol themselves. This is the paper most directly responsible for the exercise-mimetic framing applied to MOTS-c.

The mechanistic basis is the same AMPK-activation pathway discussed elsewhere in this catalogue's mitochondrial-peptide coverage: MOTS-c translocates to the nucleus under metabolic stress and modulates gene expression via AMPK-dependent regulation, and this pathway substantially overlaps with the AMPK activation that occurs during physical exertion itself, first characterised mechanistically by Kim et al. (2015, Cell Metab) in the original MOTS-c discovery work. The overlap is genuine, but 'reproduces a portion of the transcriptional programme' is a narrower and more defensible claim than 'mimics exercise'.

SS-31 contributes to this research area from a different angle. Rather than triggering exercise-like gene-expression changes, its cardiolipin-stabilising mechanism preserves the mitochondrial electron-transport efficiency that exercise training is known to improve through mitochondrial biogenesis. Siegel et al. (2013, Aging Cell) showed SS-31 restoring aged-muscle physical performance to young-mouse levels within 8 days — a mechanistically distinct route to a functionally similar endpoint (improved muscle performance) as MOTS-c, achieved by protecting existing mitochondrial function rather than inducing new adaptive gene expression.

Irisin, the cleaved and secreted product of the membrane protein FNDC5, is the other molecule most associated with the exercise-mimetic framing, following Boström et al. (2012, Nature), which reported that irisin secretion increased with exercise and drove browning of white adipose tissue in mice. Irisin is not currently part of this site's research-peptide catalogue, and it is worth noting here specifically because subsequent replication of the original browning effect has been mixed, with several groups reporting difficulty reproducing the magnitude of the initial findings and raising questions about human-relevant irisin levels versus the concentrations used in the original mouse work.

This replication difficulty with irisin is a useful comparison point for evaluating MOTS-c and SS-31's own evidence bases. Both have been replicated across multiple research groups and species to a greater extent than the original irisin browning claim, which is one reason MOTS-c and SS-31 are treated as more established within this catalogue's mitochondrial-peptide coverage than irisin-directed approaches currently are.

None of this displaces the basic point that supervised exercise training itself remains unmatched as an intervention across the endpoints these peptides are being evaluated against — cardiorespiratory fitness, muscle strength, metabolic flexibility. The mimetic framing is scientifically useful for identifying which specific molecular pathways drive which specific exercise benefit, which has translational value for populations unable to exercise adequately (severe frailty, certain neuromuscular conditions), but it is not evidence that peptide administration substitutes for physical activity in populations who can exercise.

The translational gap across this entire sub-field is the same one that recurs throughout the mitochondrial-peptide literature: mechanistic and rodent-performance data is comparatively strong, but there is no adequately powered human trial directly comparing peptide administration against a structured exercise programme on shared, pre-specified endpoints.

The research opportunity in 2026 is narrower and more useful than a general mimetic claim: identifying which specific exercise-induced adaptations each peptide reproduces (MOTS-c's transcriptional and AMPK-mediated changes, SS-31's mitochondrial-membrane protection) and testing whether combining a peptide with a low-intensity exercise protocol produces adaptations neither achieves alone, particularly in populations with limited exercise tolerance.